The anti-CD147 monoclonal antibody meplazumab, already shown to suppress SARS-CoV-2 infection, now emerges as a repurposable therapeutic for influenza (Geng et al., 2021), and our findings extend its potential application to influenza virus inhibition (Figure 8). This evidence concerns the gene BSG and influenza.